Amylyx Pharmaceuticals, Inc.
AMLX
Rank in Stocks
#4490
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Share Price
$27.25
Last synced: 2026-10-19
Market Cap
$3.42B
Change (1 day)
3.45%
Change (1 year)
77.29%
Country
US
Trade Amylyx Pharmaceuticals, Inc. (AMLX)
Category
Healthcare
Number of shares outstanding for Amylyx Pharmaceuticals, Inc. (AMLX)
Number of shares outstanding as of June 2026: 111.20M
According to Amylyx Pharmaceuticals, Inc. latest financial reports and stock price the company's current number of shares outstanding is 111.20M. At the end of December 2023 the company had 67.23M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Amylyx Pharmaceuticals, Inc. (AMLX) from 2019 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 111.20M | 63.18% |
| 2024 | 68.14M | 1.35% |
| 2023 | 67.23M | 1.09% |
| 2022 | 66.51M | 14.95% |
| 2021 | 57.86M | 2.48% |
| 2020 | 56.47M | 0.00% |
| 2019 | 56.47M | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 253.90M | 128.33% |
US
|
|
| 396.00M | 256.13% |
US
|
|
| 478.91M | 330.69% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -44.08% |
NL
|
